Todd Campbell
Long/short equity, growth, medium-term horizon, registered investment advisor

Icon's Growth Is Global

High profile patent expirations have drug companies balancing smaller research budgets against pressure to increase the number of commercialized drugs.

This dynamic is shifting the drug maker's focus from expensive internal research to outsourcing solutions from Contract Research Organizations ("CRO's) like Icon Plc (NASDAQ:ICLR).

The three catalysts likely to support Icon going forward include:

1. Drug makers will continue to outsource research and development to curb costs amid patent expiration.

2. New outsourcing services and emerging market R&D increases the company's addressable market.

3. Attractive share price metrics versus CRO peers.

The Industry

Last year, drug spending sank 1%, according to the IMS Institute for Healthcare Informatics. That marked the first ever decline in drug spending on record....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details